Immune Checkpoint Blockade in Hepatocellular Carcinoma

Extremely encouraging results from the interim analysis of the phase I/II nivolumab trial (CA209-040 trial) evaluating the efficacy of nivolumab in patients with hepatocellular carcinoma (HCC) were reported at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from May 29 to June 2, 2015 [1]. According to the report, a dose escalation study showed the safety and efficacy of 0.1–10 ml/kg of nivolumab, a monoclonal antibody against programmed cell death 1 (PD-1), in patients with HCC due to hepatitis C virus (HCV), hepatitis B virus (HBV), or without infection. Of the 47 patients with HCC, 33 (70%) had extrahepatic metastasis and six (13%) had vascular invasion. Thirty-two (68%) patients had previously been treated with sorafenib, indicating that these patients had relatively advanced liver cancers. The results of an interim analysis performed on March 12, 2015, after the treatment with the anti-PD-1 antibody, showed that 17 patients remained on the study treatment, while 30 patients terminated or discontinued the treatment because of disease progression (n=26), complete response (CR) (n=2), or adverse events (AE) (n=2, for elevated bilirubin or events unrelated to the study drug). According to the Common Terminology Criteria for Adverse Events (CTCAE) grading, the only grade 4 AE was an elevated lipase level, whereas grade 3 AEs included elevated liver enzymes [aspartate aminotransferase (AST) (11%, n=5) and alanine aminotransferase (ALT) (9%, n=4)]. None of the patients developed serious liver dysfunction or autoimmune disease.

The overall objective response rate was 19% (n=8), including the two patients who achieved CR (5%). Disease control rates were 67% (n=28) for stable disease (SD) or better and 33% (n=14) for progressive disease (PD), indicating an extremely favorable study outcome (table 1).

Waterfall plots revealed tumor size stabilization or reduction in 67% of the patient cohorts with HBV, HCV and those without infection. Regarding the durability of treatment responses, the two patients with CR achieved this within three months of therapy and this was sustained for 12–18 months or longer. Another patient had SD until 11 months after the initiation of treatment and subsequently achieved a partial response (PR), to almost a CR, at approximately 13 months. Patients with PR and SD had sustained disease, and none of them had PD due to acquired tolerance. These outcomes show excellent durability of treatment using the anti-PD-1 antibody in HCC, as observed in other types of cancer. A durable response is
the most characteristic and favorable feature of the effect of immune checkpoint inhibitors. The two patients who achieved CR within three months maintained the response longer than 15 months despite cessation of anti-PD-1 antibody treatment within a few months of achieving CR. Similarly, most patients with PR achieved this at ≤3 months, except one patient who achieved PR at approximately four months. The ASCO report describes cases of the disappearance of bilobar multiple HCCs after six weeks of therapy accompanied by a drastic decline of alpha-fetoprotein level from 21,000 to 283 IU/mL. A reduction in tumor size from approximately 10 cm to nearly 2 cm was observed in one patient after 48 weeks, revealing a durable response. Furthermore, the overall survival rate was 62% at 12 months, which is a highly promising outcome considering that the prognostic factors of tumors were poor in this patient cohort.

In summary, monotherapy with the anti-PD-1 antibody, nivolumab, had a manageable safety profile even in patients with HCC, which was comparable with its safety profile in other types of cancer. It was also safe in patients with HBV and HCV infection. The treatment showed a high response rate that was groundbreaking for an immunotherapy, with long-lasting durable responses. Durable responses were observed at all dose levels regardless of etiology (without infection, HBV, and HCV cohorts).

A phase I/II study with the expansion cohorts of non-infected patients who are sorafenib-naive or -intolerant, or have PD after sorafenib treatment (50 patients each), HCV-infected patients (n=50), and HBV-infected patients (n=50) was designed with a fixed dose of 3 mg/kg of nivolumab (total number of patients = 200). The trial is currently ongoing and the outcome is eagerly awaited.

The immune checkpoint molecule PD-1 was first discovered by Prof. Tasuku Honjo of Kyoto University Graduate School of Medicine in 1992 [2–4]. Ishida, Honjo, and colleagues later used mice lacking the PD-1 to show that the gene encodes a receptor that "applies the break to immune reaction" [2]. In 2000, the ligands of PD-1 (PD-L1 and PD-L2) were discovered by the Honjo group at Kyoto University in collaboration with the Genetics Institute in the United States. In 2002, Iwai et al. used a mouse model to show that inhibition of the interaction between PD-1 and its ligand markedly enhanced immunostimulation and thus, antitumor effects [3]. Based on this finding, cooperation between Ono Pharmaceutical in Japan and Medarex in the United States resulted in the development of the human anti-PD-1 antibody, nivolumab, in 2006. The monoclonal antibody was approved by the Food and Drug Administration (FDA) for use in clinical trials as a new investigational drug in the same year. In 2009, Ono Pharmaceutical and Bristol-Myers Squibb, which merged with Medarex, start-

---

**Table 1. Best overall responses**

<table>
<thead>
<tr>
<th></th>
<th>Non-infected (n=21)</th>
<th>HCV (n=11)</th>
<th>HBV (n=10)</th>
<th>Total evaluable (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>2 (10)</td>
<td>0</td>
<td>0</td>
<td>2 (5)</td>
</tr>
<tr>
<td>PR</td>
<td>1 (5)</td>
<td>4 (36)</td>
<td>1 (10)</td>
<td>6 (14)</td>
</tr>
<tr>
<td>SD</td>
<td>10 (48)</td>
<td>5 (45)</td>
<td>5 (50)</td>
<td>20 (48)</td>
</tr>
<tr>
<td>PD</td>
<td>8 (38)</td>
<td>2 (18)</td>
<td>4 (40)</td>
<td>14 (33)</td>
</tr>
<tr>
<td>Ongoing response, n (%)</td>
<td>3/3 (100)</td>
<td>3/4 (75)</td>
<td>0</td>
<td>6/8 (75)</td>
</tr>
<tr>
<td>Objective response, n (%)</td>
<td>3 (14)</td>
<td>4 (36)</td>
<td>1 (10)</td>
<td>8 (19)</td>
</tr>
<tr>
<td>Disease control rate, n (%)</td>
<td>13 (62)</td>
<td>9 (82)</td>
<td>6 (60)</td>
<td>28 (67)</td>
</tr>
</tbody>
</table>

Responses assessed by RECIST 1.1. Reproduced with permission from El-Khoueiry AB, et al. [1].
ed clinical trials with nivolumab. In July 2014, the anti-PD-1 antibody was first approved as a treatment drug for advanced melanoma in Japan, followed by its approval in December 2014 in the United States and in June 2015 in Europe. Another anti-PD-1 antibody, pembrolizumab, was also approved for the treatment of advanced melanoma in September 2014 in the United States. Since then, the anti-PD-1 antibody has been actively evaluated in various clinical trials for the treatment of more than 30 types of cancers, including non-small cell lung, prostate, colon, and renal cancers among others, with satisfactory outcomes.

In 1995, Dr. James Allison of the University of Texas MD Anderson Cancer Center discovered cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which also functions as a break in immune cells [5]. In the following year, the same research group reported the disappearance of tumors in mice after the administration of an antibody that inhibits the function of CTLA-4 [6]. Subsequently, an antibody against the immune checkpoint molecule CTLA-4, developed by Bristol-Myers Squibb under the name of ipilimumab, was approved by the FDA as a treatment drug for advanced melanoma in the United States in March 2011, in Europe in July 2011, and in Japan in July 2015 [7]. Ipilimumab is currently approved for advanced melanoma in more than 50 countries worldwide.

A report published in *Journal of Hepatology* in 2013, described the results of a clinical trial involving patients with HCC, which showed that the incidence of side effects was slightly higher with the anti-CTLA-4 antibody than with the anti-PD-1 antibody [8, 9] (table 2).

When cancer cells develop, the tumor-associated antigens are recognized and presented by antigen-presenting cells such as dendritic cells, leading to the activation of immature T-cells that become CD8-positive T-cells (cytotoxic T-cells) in the lymph nodes (priming phase). These T-cells circulate in the blood and attack cancer cells by releasing molecules such as perforin and granzymes at the tumor site (effector phase). However, T-cell receptor recognition of tumor-associated antigens leading to the attack of cancer cells by CD8-positive T-cells is associated with the binding of cytokines, particularly interferon-γ (IFN-γ) secreted by cytotoxic T-lymphocytes (CTL), to the IFN-γ receptor on the tumor surface. Subsequently, IFN-γ induces the expression of PD-L1 or PD-L2 molecules on the cancer surface, both of which bind PD-1, to escape from the CTL attack. Therefore, an IFN-γ signal is sent to the CTL to downregulate the antitumor immune response, allowing the tumor to escape from the attack of CTLs (immune escape or immune tolerance) (fig. 1).

**Table 2. Clinical trials of immune checkpoint inhibitors in HCC**

<table>
<thead>
<tr>
<th>Drug</th>
<th>HBV/HCV eligibility</th>
<th>Dosage</th>
<th>Results</th>
<th>Treatment-related grade 3–4 AE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremelimumab (anti-CTLA-4)</td>
<td>HCV + only (21)</td>
<td>15 mg/kg every 90 days x 4</td>
<td>PR 17.6% (3/17)</td>
<td>AST/ALT (45), syncope (10), diarrhea (5), neutropenia (5), rash (5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DCR 76.4% child B (42.9%) prior therapy (57.4%)</td>
<td></td>
</tr>
<tr>
<td>Nivolumab (anti-PD-1)</td>
<td>Non-infected (24)</td>
<td>0.1 – 10 mg/kg every 2 months</td>
<td>RR 19% (2 CR, 6 PR/42) child B (2%) prior systemic therapy (100%)</td>
<td>AST/ALT (11/9), lipase (8), anemia (2), fatigue (2)</td>
</tr>
<tr>
<td></td>
<td>HCV (12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HBV (11)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DCR=disease control rate; RR=response rate. Modified with permission from El-Khoueiry AB, et al. [1] and Sangro B, et al. [8].
The anti-PD-1 antibody blocks the binding of PD-1 on activated T-cells to PD-L1 or PD-L2 on the antigen presenting cells or tumor cells, thus releasing the immune escape status and resulting in the recovery of the T-cell attack on tumor cells (fig. 2). Unlike cytotoxic chemotherapy or molecular targeted therapy, the anti-PD-1 antibody restores the human immune system, an intrinsic powerful and precise weapon, allowing it to regain its original strength to attack and kill cancer cells [10–21].

Another immune checkpoint inhibitor, the anti-PD-L1 antibody, functions in a similar manner [22]. In addition, PD-L1 and tumor infiltrating lymphocytes may be predictive biomarkers for the efficacy of the anti-PD-1 antibody [23]. A study suggested that the Kupffer phase of Sonazoid®-enhanced contrast ultrasonography [24] could be a predictive imaging biomarker of the response to the anti-PD-1 antibody in liver cancers.

The outcomes of monotherapy with the anti-PD-1 antibody in patients with HCC were reported in the ASCO meeting as mentioned above. The anti-PD-1 antibody, nivolumab, was approved in the United States for the treatment of advanced melanoma and non-small cell lung cancer, and similar outcomes are expected from currently ongoing clinical trials in other cancers including HCC [25–30].

Liver cancer requires different treatment strategies from those applied in other solid tumors or hematologic malignancies because they are extremely heterogeneous cancers that lack major driver mutations, and because the use of hepatotoxic drugs is not possible. With these issues in mind, the outcomes of the phase I/II trial are quite promising with regards to the efficacy as well as safety of the drug. Therefore, the initiation of a future phase III study.
of the anti-PD-1 antibody is eagerly awaited. We envisage that this breakthrough agent will be approved for the treatment of HCC in a speedy manner.

Clinical trials of the anti-PD-1/PD-L1 antibody for the treatment of HCC may be initiated by several pharmaceutical companies, with positive results expected. The unmet needs in the treatment of HCC are present at various stages (early, intermediate, and advanced stages) and in various settings, such as neoadjuvant and/or adjuvant settings before and after resection [31, 32] or ablation [33, 34], adjuvant settings after transcatheter arterial chemoembolization [35, 36], and first- or second-line treatment for advanced HCC. In combination treatment strategies with these locoregional therapies, the blockade of this novel PD-1/PD-L1 pathway will play a major role. Alongside this pathway, expectations are also high regarding its combination with other drugs, such as the anti-CTLA-4 antibody and/or molecular targeted agents (surafenib and/or incoming new agents) [37, 38]. At this year’s ASCO meeting, combination therapy with nivolumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody) was shown to be more effective than monotherapy with each drug in patients with advanced melanoma [30].

This particular field of immunotherapy has developed rapidly in recent years, not only for the treatment of melanoma/lung cancer, but also for other types of cancers. The FDA granted a “Breakthrough Therapy Designation” to nivolumab and pembrolizumab in September 2014 for lung cancer. Therefore, these anti-PD-1 antibodies are expected to be approved very soon for the treatment of various types of cancers for routine clinical use. Depending on the results of the expansion cohort study or the status of drug development in other pharmaceutical companies, immune checkpoint inhibitors are expected to be approved for the treatment of HCC in the very near future.

The recognition of Immuno-Oncology as the “Breakthrough of the Year” in 2013 by the editors of Science, a scientific journal in the United States, is well publicized. The outcomes of treatment strategies for liver cancer are expected to improve in the near future through
combination therapy based on these immune checkpoint inhibitors and locoregional therapies, other agents such as molecular targeted agents, or other immune mediated agents with antagonistic or agonistic effect on immune checkpoint system inhibitors. This is a real paradigm shift, not only in drug therapy, but also in the treatment of liver cancer. Immune checkpoint inhibitors will play a major role in the evolution of HCC treatment, as implicated by their current use in the treatment of other types of cancer.

In conclusion, the first stage of systemic chemotherapy was based on cytotoxic agents, and the second stage was characterized by molecular targeted agents. Today, we move forward to the third stage of systemic cancer therapy with immune checkpoint inhibitors, namely, anti-PD-1, -PD-L1, and -CTLA-4 antibodies. Immune checkpoint inhibitors may soon become the mainstream treatment strategy for HCC, and our attention will remain focused on these developments in the future.

References


